IGC
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related dementias. The company operates as a single reportable segment within the Life Sciences sector, having previously maintained an Infrastructure segment that is no longer actively managed. Its lead drug candidate, IGC-AD1, is a partial CB1 receptor agonist currently in a Phase 2 clinical trial named CALMA, which targets agitation and sleep disturbances in patients with Alzheimer’s dementia. The pipeline includes early-stage assets such as TGR-63, LMP, IGC-M3, IGC-1C, and IGC-1A, which target mechanisms including amyloid-beta plaque formation, neuroinflammation, tau protein aggregation, and metabolic disorders like type 2 diabetes and obesity. IGC Pharma utilizes artificial intelligence and machine learning to develop predictive models for early detection and risk stratification, specifically through the MINT-AD tool, which integrates multimodal data including longitudinal aging data, clinical records, neuroimaging, and omics data. The company leverages internal contract research organization capabilities and maintains manufacturing and processing facilities to support its vertically integrated operations. Founded in 2005, the company serves patients and caregivers globally, with data sources for its AI models representing populations from North, Central, and South America, as well as Asia.

Summarised from the company's own disclosures, fiscal year ended Jun 2025

Industry Biotechnology Homepage igcinc.us
Sector Healthcare IR page investor.igcpharma.com
Tags
alzheimer's disease, neurodegenerative diseases, clinical-stage, drug development, artificial intelligence, machine learning, cb1 receptor agonists, amyloid-beta, tau protein, metabolic disorders, early detection, risk stratification, IGC-AD1, CALMA, TGR-63, LMP, IGC-M3, IGC-1C, IGC-1A, MINT-AD
Press page igcpharma.com/category/news

Metrics

Valuation  
Market cap $ 30.749M
Market cap (USD) $ 30.749M
P/E -2.99
PEG —
P/BV 4.73
P/S 24.19
P/OCF -6.41
P/FCF -6.27
Dividend yield —
Turnover / mcap —
Returns  
ROE -104.3%
ROI -110.2%
ROIC -86.4%
Profit margin -560.3%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 1.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Revenue 1.271M 1.345M 911K 289K 898K 4.072M 5.116M 2.193M 580.372K 6.367M 7.68M 2.273M 8.03M 4.2M 4.074M 35.339M 2.188M
Net profit -7.122M -13M -11.506M -15.016M -8.811M -7.315M -4.097M -1.786M -1.867M -2.808M -4.614M -3.023M -2.252M -7.752M -20.241M -521.576K -5.215M
Free cash flow -4.907M -5.337M -7.357M -7.669M -12.27M -13.066M -3.345M -2.067M -1.537M -279.887K -2.66M -1.751M -147.879K -5.028M -2.92M -10.607M -8.573M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Share price 0.29 0.4 0.34 0.95 1.79 0.49 2.08 0.56 0.47 0.52 0.44 0.78 0.2 0.18 — 4.94 4.32
Price performance 12m -0.29 0.18 -0.64 -0.47 2.66 -0.76 2.7 0.2 -0.09 0.19 -0.44 2.9 0.11 — — 0.14 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) 752,926 557,813 84,000 133,000 175,000 125,000 107,000 39,000 34,000 37,000
↳ YoY growth -21.8% -25.9% -84.9% +58.3% +31.6% -28.6% -14.4% -63.6% -12.8% +8.8%
↳ 5y CAGR -14.4% -12.2% -31.7% -33.1% -28.9% -30.2% -28.1% -14.2% -23.9% -26.7%
Borrowings, current (USD) 0.00 0.00 50,000 50,000 304,000 3,000 3,000 3,000 3,000 —
Borrowings, non-current (USD) 452,080 — — 0.00 276,000 144,000 141,000 137,000 134,000 —
Lease liabilities (USD) — — 0.00 574,000 495,000 464,000 340,000 208,000 104,000 9,000
Cash and deposits (USD) 538,029 1.66M 25.6M 7.26M 14.5M 10.5M 3.2M 1.2M 405,000 207,000
Intangible assets (USD) 0.00 127,826 184,000 252,000 407,000 917,000 1.17M 1.62M 1.85M 5.27M
Right-of-use assets (USD) — — 0.00 574,000 488,000 450,000 326,000 198,000 98,000 8,000
Net debt (borrowings + leases - cash) (USD) -85,949 -1.66M -25.6M -6.63M -13.5M -9.85M -2.71M -850,000 -164,000 —
Cash flow detail
Operating cash flow (USD) -1.39M -1.93M -3.33M -8.68M -10.8M -7.46M -7.05M -5.2M -4.8M —
Purchases of property, plant and equipment (USD) -145,677 -135,731 -15,000 -4.39M -1.47M -207,000 -310,000 -138,000 -112,000 —
Purchases of intangible assets (USD) — — -45,000 -77,000 -122,000 -535,000 -309,000 -377,000 -370,000 —
Change in receivables (cash effect) (USD) -144,711 -33,768 474,000 -49,000 -42,000 50,000 5,000 -25,000 -8,000 —
Change in inventories (cash effect) (USD) 0.00 -424,710 239,000 -4M -1.23M 1.93M 897,000 1.01M 180,000 —
Change in payables (cash effect) (USD) — — -30,000 442,000 -287,000 504,000 -451,000 243,000 106,000 —
Interest paid (cash effect) (USD) -93,648 -30,742 -14,000 -8,000 0.00 0.00 — — — —
Income taxes paid (cash effect) (USD) -14,431 0.00 — — — — — — — —
Share-based compensation (USD) 203,200 576,251 610,000 521,000 703,000 7M 5.5M 4.6M 4.3M —
Operating cash flow before change in receivables (USD) -1.25M -1.9M -3.8M -8.63M -10.8M -7.51M -7.05M -5.17M -4.79M —
Free cash flow (OCF - PPE - intangibles) (USD) -1.54M -2.07M -3.35M -13.1M -12.4M -8.2M -7.67M -5.71M -5.28M —
Income detail
Research and development expense (USD) — 137,000 1.26M 1.01M 929,000 2.33M 3.5M 3.77M 3.66M —
↳ 5y CAGR +91.2% +24.6% +29.3%
Total comprehensive income (USD) — -1.8M -4.46M -7.75M -8.74M -15.2M -11.9M -13M -7.15M —
Comprehensive income to owners (USD) — -1.8M -4.46M -7.75M -8.74M -15.2M -11.9M -13M -7.15M —
Provision for credit losses (USD) 6,980 15,614 — — 0.00 1.72M 126,000 93,000 13,000 —
Credit cost ratio (credit losses / average receivables) (%) 0.8% 2.4% — — 0.0% 1,145.3% 108.6% 127.4% 35.6% —
Reported Jul 14, 2017 Jun 14, 2019 Jul 13, 2020 Aug 19, 2020 Jun 23, 2022 Jun 23, 2022 Jul 7, 2023 Jun 24, 2024 Jun 27, 2025 May 15, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Canada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer’s disease. Agitation is one of the hardest symptoms for families to manage.

POTOMAC, Md. – November 05, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, “Method and Composition for Treating CNS Disorders”.  
The patent covers the composition of IGC-AD1, an investigational oral therapy for agitation in Alzheimer’s.  

With this grant, IGC-AD1 is protected by issued patents from the same patent family in all three North American markets: the United States (U.S. Patent No. 12,465,589), Canada, and Mexico (Mexican Patent No. 409,414). In total, IGC-AD1 is protected by 5 granted patents, with 10 more applications pending worldwide. 

“Strong patent protection is central to our strategy for IGC-AD1,” said Ram Mukunda, CEO of IGC Pharma. “These patents strengthen our intellectual property portfolio. Our vision is to combine compelling clinical evidence with patent protection that supports long-term commercial value and helps attract major pharmaceutical partners to advance development and, if approved, expand patient access.” 

IGC-AD1 is being evaluated in CALMA, a randomized, double-blind, placebo-controlled Phase 2 trial for agitation in Alzheimer’s dementia. CALMA completed enrollment in September 2026 and is in its final dosing period. Topline results will follow database lock and unblinding. 

Agitation affects a large share of people living with Alzheimer’s disease and is one of the hardest parts of the disease for families and caregivers to manage. IGC-AD1 is an investigational oral liquid designed to address multiple biological mechanisms implicated in agitation, including neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation. 

About IGC Pharma, Inc. 

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. Supported by its patent portfolio and commitment to innovation, IGC Pharma is advancing breakthrough therapies. 

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding completion of dosing and patient follow-up in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia; the timing of database lock, unblinding, topline analysis, and reporting of results; potential further clinical development and regulatory submissions; and the Company’s patent protection and partnering plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including delays in trial completion, data collection, verification, and analysis; uncertainties regarding the safety and efficacy of IGC-AD1 and whether CALMA will meet its endpoints; the need for additional clinical trials and regulatory review; financing needs; risks that issued patents may be challenged, narrowed, or circumvented; and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and Quarterly Reports on Form 10-Q. There can be no assurance regarding the timing or outcome of the CALMA trial, regulatory approval, commercialization, or any pharmaceutical partnership. IGC-AD1 is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. The Company undertakes no obligation to update forward-looking statements except as required by law.  

Investor Relations Contact Andres Sanchez / Investor Relations 
+1 301-983-0998 / +1 (202) 569-2566 
[email protected]  

Media: Kiran Mukunda, [email protected]  

← Back to Press Releases

Recent Press Releases

IGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment

 

October 13, 2026

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026

 

September 28, 2026

Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst

 

August 28, 2026

All Press Releases →

Subscribe to Our Newsletter

Subscribe to get our latest content by email.

Subscribe

COMPANY

FINANCIALS

TRADING & DATA

X-twitter Facebook-f Linkedin

GDPR Cookie Banner

This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services.

You can manage your preferences at any time through our cookie settings panel.

Accept All Reject All Settings

Close GDPR Cookie Settings

  • Privacy Overview
  • Necessary Cookies
  • Google Analytics & Performance
  • Marketing
  • Cookie Policy

Powered by  GDPR Cookie Compliance (opens in a new tab)

Privacy Overview

This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services.

In accordance with applicable privacy laws, including the California Consumer Privacy Act (CCPA) and other relevant regulations, you have the right to accept, reject, or customize the use of non-essential cookies, as well as to opt out of the sale or sharing of your personal information for targeted advertising.

You can manage your preferences at any time through our cookie settings panel.

Necessary Cookies

These cookies are essential for the proper functioning, security, and accessibility of the website. They include functionalities such as session management, security controls, and storage of your privacy preferences.

  • These cookies do not require user consent.
  • They do not store personally identifiable information for tracking purposes.

Without these cookies, the website cannot function correctly.

Enabled Disabled

Google Analytics & Performance

We use analytics tools such as Google Analytics (cookies: _ga, _gid) to collect information about how users interact with the website (e.g., pages visited, time spent, navigation patterns).

  • Purpose: Measure and improve website performance and usability.
  • Data may be transferred to third parties (e.g., Google).
  • These cookies may enable cross-site tracking and behavioral analysis.

These cookies are only activated with your explicit consent (opt-in). You may disable them at any time via the settings panel.

Enabled Disabled

Marketing

We use marketing and advertising technologies, including:

  • Meta/Facebook Pixel (cookie: _fbp)
  • Google DoubleClick / Google Ads services
  • HubSpot tracking cookie (cookie: _hubspotutk)
  • Pixelyoursite: (pys_fb_pixel_traffic_source)

These cookies and pixels allow us to:

  • Deliver personalized advertisements.
  • Measure campaign effectiveness.
  • Track user interactions across websites (profiling).

Key considerations:

  • They may involve data sharing with third-party platforms.
  • They enable cross-site tracking and user profiling.
  • They are subject to strict regulatory requirements and require explicit prior consent (opt-in).

You may opt out of these cookies at any time. Disabling them will not affect core site functionality but may limit personalized experiences.

Third-Party Integrations and External Services

Our website integrates services provided by third parties, including but not limited to:

  • Analytics & Advertising: Google Analytics, Google Tag Manager, DoubleClick
  • Marketing & CRM: HubSpot, ConvertKit, Mailchimp
  • User Experience & Tracking: Hotjar
  • Social Media Integrations: Facebook, Reddit
  • Accessibility Services: Userway

These services may:

  • Process personal data outside of our direct control.
  • Transfer information to external jurisdictions.
  • Introduce third-party dependencies and potential security risks.

We ensure that:

  • Each integration is assessed based on necessity and proportionality.
  • Vendors are evaluated under Third-Party Risk Management practices.
  • Security measures such as Content Security Policy (CSP) are implemented to restrict unauthorized domains.

Your Privacy Rights

Depending on your jurisdiction, you may have the right to:

  • Access, correct, or delete your personal data.
  • Opt out of the sale or sharing of your data.
  • Withdraw consent for non-essential cookies at any time.

To exercise these rights, please use the cookie management tool available on this site or contact us directly.

Enabled Disabled

Cookie Policy

To access further regulatory disclosures concerning our Cookie Policy , tracking mechanisms, and corporate data governance,. You will find definitive guidance on how to audit, restrict, or remove these cookies through your enterprise web browser settings.

Enable All Reject All Save Changes

POTOMAC, Maryland – October 13, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM™, a new application layer designed to bring its patent-pending MINT-AD™ Alzheimer’s AI platform closer to real-world healthcare applications, including early Alzheimer’s risk stratification, cognitive health tracking, clinical trial optimization, and personalized brain-health programs. 

The introduction represents an important expansion of IGC Pharma’s Artificial Intelligence and Alzheimer’s disease strategy, moving beyond predictive research models toward potentially scalable commercial applications for healthcare providers, memory clinics, pharmaceutical companies, clinical research organizations, and consumer brain-health platforms. 

PRISM™ is designed to translate AI-generated Alzheimer’s risk insights into structured workflows that support risk assessment, ongoing cognitive monitoring, patient engagement, and potential earlier intervention. The Company is evaluating business-to-business (B2B), business-to-business-to-consumer (B2B2C), and online commercialization opportunities as it develops a broader AI-enabled brain-health ecosystem. 

“PRISM™ is the next step in our Alzheimer’s AI strategy,” said Ram Mukunda, Chief Executive Officer of IGC Pharma. “MINT-AD™ was designed to help identify risk and forecast cognitive decline. PRISM™ is designed to move those insights into action through structured workflows that may support individuals, clinicians, care teams, and commercial partners seeking earlier, more informed approaches to brain health. We believe PRISM™ has the potential to address a significant gap between Alzheimer’s risk prediction and practical intervention.”

Targeting a Multitrillion-Dollar Dementia Healthcare Challenge 

Alzheimer’s disease remains one of the world’s most significant neurological and healthcare challenges, with disease-related changes potentially beginning years before noticeable cognitive impairment or dementia develops. IGC Pharma has previously cited estimates suggesting that more than 400 million individuals worldwide may have early Alzheimer’s pathology, potentially placing them at increased risk of developing the disease. The Company has also cited estimates placing the global economic burden of dementia above $1.3 trillion annually, with projected costs reaching approximately $2.8 trillion by 2030. These figures underscore the need for scalable technologies that support early Alzheimer’s risk assessment, AI-powered cognitive monitoring, precision medicine, and personalized brain-health management.  
 
IGC believes that connecting predictive AI technologies with structured healthcare workflows could create opportunities to address unmet needs in Alzheimer’s research, clinical care, and long-term brain-health monitoring. 

MINT-AD™ and PRISM™: Moving Alzheimer’s AI From Prediction Toward Action 

MINT-AD™, IGC Pharma’s Multimodal Interpretable Transformer for Alzheimer’s, is designed to identify and stratify Alzheimer’s risk, forecast cognitive decline, and generate interpretable risk insights from complex health, demographic, lifestyle, cognitive, and other data. According to prior Company disclosures, MINT-AD™ has been developed using globally diverse datasets, supporting its disease-specific approach to Alzheimer’s risk prediction and longitudinal assessment. 

PRISM™ extends MINT-AD™ by connecting predictive insights to practical brain-health applications, including: 

  • Early Alzheimer’s Risk Assessment: AI-supported identification and stratification of individuals who may benefit from additional clinical evaluation; 

  • Cognitive Health Monitoring: longitudinal workflows designed to support tracking of brain-health indicators over time; 

  • Clinical Trial Optimization: potential applications in patient stratification, trial recruitment, and research workflows; 

  • Healthcare Provider Integration: structured information and monitoring workflows for physician practices, memory clinics, and care teams; 

  • Consumer Brain Health: potential online programs supporting education, risk-factor intake, engagement, and ongoing monitoring. 

Many individuals with early memory concerns or elevated Alzheimer’s risk factors may not receive a clear pathway for risk assessment, monitoring, or structured intervention. PRISM™ is designed for a different model: one in which AI-supported risk stratification helps identify individuals earlier, connect them to structured brain-health workflows, and support longitudinal monitoring earlier in the disease continuum. 

Commercial Strategy Targets Healthcare, Pharmaceutical and Consumer Markets 

IGC Pharma is evaluating multiple commercialization pathways designed to expand the potential reach of its Alzheimer’s AI and digital healthcare technologies. Potential opportunities include licensing PRISM™ and MINT-AD™ to physician practices, memory clinics, pharmaceutical companies, clinical trial sponsors, healthcare networks, insurers, and other healthcare organizations. The Company is also exploring partnerships that could integrate PRISM™ into existing clinical and consumer brain-health services, alongside a potential direct-to-consumer online platform focused on education, cognitive health engagement, and longitudinal monitoring. These opportunities remain under evaluation.  

PRISM™ is an IGC Pharma platform. Where PRISM™ is deployed with health systems, medical societies, community organizations or public health programs, those implementations are delivered under the branding and governance of the partner program and its sponsoring organization. Participant-facing materials, program identity and the use of program data in those deployments are determined by the partner program, and references to PRISM™ in that context describe the underlying technology rather than the program itself. 

AI Research Recognition and Alzheimer’s Platform Expansion  

IGC Pharma’s Alzheimer’s AI work has previously been recognized in connection with the National Institute on Aging PREPARE Challenge, including recognition involving clean-code development, reproducibility, usability, disproportionate impact, and model generalization. The Company believes this recognition supports its AI research capabilities as it advances MINT-AD™ and PRISM™ toward practical healthcare and commercial applications. IGC Pharma is also developing its patent-pending Agentic Harmonization Assistant (aha™), an AI-enabled platform designed to integrate fragmented Alzheimer’s and aging-related biomedical datasets. In a previously reported representative internal workflow, aha™ reduced data harmonization time from approximately 28 hours to 2.5 hours, representing an approximately 90% reduction in processing time. Results may vary depending on dataset complexity, data quality, and workflow requirements.  

By advancing MINT-AD™, PRISM™, and aha™, IGC Pharma is pursuing a disease-focused AI strategy across Alzheimer’s risk prediction, data harmonization, clinical-trial optimization, cognitive health monitoring, and potential commercial brain-health applications. 

Alzheimer’s AI Development Complements IGC Pharma’s Clinical-Stage Alzheimer’s Strategy 

PRISM™ complements IGC Pharma’s disease-focused Alzheimer’s strategy, which includes the Company’s lead investigational drug candidate, IGC-AD1, being evaluated in the Phase 2 CALMA clinical trial for agitation in Alzheimer’s dementia. The Company recently announced completion of enrollment in CALMA, with 168 participants randomized across clinical sites in the United States and Canada, and topline results anticipated in the fourth quarter of 2026.  
 
Building Toward a Broader Alzheimer’s AI Commercialization Strategy 

With PRISM™, MINT-AD™, and aha™, IGC Pharma is building a portfolio of complementary technologies intended to address different stages of Alzheimer’s research and healthcare delivery. 

MINT-AD™ focuses on identifying and forecasting Alzheimer’s risk, PRISM™ connects those insights to structured monitoring and engagement workflows, and aha™ supports harmonizing and analyzing complex biomedical data. The Company believes this integrated approach may support future partnerships, licensing opportunities, and commercial deployment across healthcare, life sciences, clinical development, and consumer brain-health markets. 

About IGC Pharma 

IGC Pharma, Inc . (NYSE American: IGC) is a clinical-stage biotechnology company developing investigational therapies for Alzheimer’s disease and AI-enabled technologies supporting drug discovery, clinical research, cognitive risk assessment, and brain-health monitoring. Its lead therapeutic candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA clinical trial for agitation in Alzheimer’s dementia. The Company’s AI portfolio includes MINT-AD, PRISM, and the Agentic Harmonization Assistant (AHA), which are being developed to support Alzheimer’s research and potential healthcare applications.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding MINT-AD, PRISM, AHA, AI-enabled Alzheimer’s risk stratification, brain-health intervention workflows, longitudinal assessment, data harmonization, potential deployment, potential commercialization pathways, software licensing, clinical-trial recruitment and stratification, payer, provider, life-sciences, healthcare, consumer-facing, online, and partner applications, CALMA, IGC-AD1, and the Company’s broader Alzheimer’s therapeutics and AI-enabled healthcare strategy. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to technology development and validation, data access and rights, privacy and security requirements, regulatory considerations, software performance, market acceptance, commercialization, third-party partnerships, clinical development, trial timelines and outcomes, financing needs, and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and Quarterly Reports on Form 10-Q. 

MINT-AD, PRISM, and AHA are investigational AI-enabled platforms. They are not approved or cleared as diagnostic products and are not intended to replace clinical judgment or provide medical diagnosis or treatment decisions. The Company undertakes no obligation to update forward-looking statements except as required by law.

**Investor Relations Contact

**Andres Sanchez 
Investor Relations 
[email protected]  
+1 301-983-0998 / +1 (202) 569-2566  

Facebook

X

LinkedIn

Recent Post

IGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment

October 13, 2026

Read More »

How Sleep Supports Brain Health  

September 28, 2026

Read More »

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026  

September 28, 2026

Read More »

Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst

August 28, 2026

Read More »

Alzheimer’s Across Borders: A Global look at regional patterns and drivers of Alzheimer’s Disease

August 25, 2026

Read More »

Follow Us

Twitter Facebook-f Linkedin

Related Posts

IGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment

POTOMAC, Maryland – October 13, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today

Read More »

How Sleep Supports Brain Health  

Contrary to common belief, sleep is a very active process that keeps our body (and especially our brain) in tip-top shape. It turns out that taking good care of your

Read More »

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026  

POTOMAC, Maryland – September 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead

Read More »

Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst

POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced

Read More »

Alzheimer’s Across Borders: A Global look at regional patterns and drivers of Alzheimer’s Disease

Regional differences in Alzheimer’s Disease prevalence are often linked with factors such as health infrastructure, socioeconomic status, and lifestyle choices. Addressing these disparities requires a deeper understanding of how culture,

Read More »

Subscribe to Our Newsletter

Subscribe to get our latest content by email

Subscribe

SCIENCE

COMPANY

NEWS

TRADING & DATA

X-twitter Facebook-f Linkedin

This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services.

You can manage your preferences at any time through our cookie settings panel. 

Accept All Reject All Settings

Change cookie settings

Close GDPR Cookie Settings

  • Privacy Overview
  • Necessary Cookies
  • Google Analytics & Performance
  • Marketing
  • Cookie Policy

Powered by  GDPR Cookie Compliance

Privacy Overview

This website uses cookies and similar tracking technologies to enhance your browsing experience, analyze site traffic, provide personalized content, and support marketing activities. These technologies may involve the collection and processing of personal data, including through third-party services. 

In accordance with applicable privacy laws, including the California Consumer Privacy Act (CCPA) and other relevant regulations, you have the right to accept, reject, or customize the use of non-essential cookies, as well as to opt out of the sale or sharing of your personal information for targeted advertising. 

You can manage your preferences at any time through our cookie settings panel. 

Necessary Cookies

These cookies are essential for the proper functioning, security, and accessibility of the website. They include functionalities such as session management, security controls, and storage of your privacy preferences. 

  • These cookies do not require user consent. 

  • They do not store personally identifiable information for tracking purposes. 

Without these cookies, the website cannot function correctly. 

Enable or Disable Cookies Enabled Disabled

Google Analytics & Performance

We use analytics tools such as Google Analytics (cookies: _ga, _gid) to collect information about how users interact with the website (e.g., pages visited, time spent, navigation patterns). 

  • Purpose: Measure and improve website performance and usability. 

  • Data may be transferred to third parties (e.g., Google). 

  • These cookies may enable cross-site tracking and behavioral analysis. 

These cookies are only activated with your explicit consent (opt-in). You may disable them at any time via the settings panel. 

Enable or Disable Cookies Enabled Disabled

Marketing

We use marketing and advertising technologies, including: 

  • Meta/Facebook Pixel (cookie: _fbp) 

  • Google DoubleClick / Google Ads services 

  • HubSpot tracking cookie (cookie: _hubspotutk) 

  • Pixelyoursite: (pys_fb_pixel_traffic_source) 

These cookies and pixels allow us to: 

  • Deliver personalized advertisements. 

  • Measure campaign effectiveness. 

  • Track user interactions across websites (profiling). 

Key considerations: 

  • They may involve data sharing with third-party platforms. 

  • They enable cross-site tracking and user profiling. 

  • They are subject to strict regulatory requirements and require explicit prior consent (opt-in). 

You may opt out of these cookies at any time. Disabling them will not affect core site functionality but may limit personalized experiences. 

Third-Party Integrations and External Services 

Our website integrates services provided by third parties, including but not limited to: 

  • Analytics & Advertising: Google Analytics, Google Tag Manager, DoubleClick 

  • Marketing & CRM: HubSpot, ConvertKit, Mailchimp 

  • User Experience & Tracking: Hotjar 

  • Social Media Integrations: Facebook, Reddit 

  • Accessibility Services: Userway 

These services may: 

  • Process personal data outside of our direct control. 

  • Transfer information to external jurisdictions. 

  • Introduce third-party dependencies and potential security risks. 

We ensure that: 

  • Each integration is assessed based on necessity and proportionality. 

  • Vendors are evaluated under Third-Party Risk Management practices. 

  • Security measures such as Content Security Policy (CSP) are implemented to restrict unauthorized domains. 

Your Privacy Rights 

Depending on your jurisdiction, you may have the right to: 

  • Access, correct, or delete your personal data. 

  • Opt out of the sale or sharing of your data. 

  • Withdraw consent for non-essential cookies at any time. 

To exercise these rights, please use the cookie management tool available on this site or contact us directly. 

Enable or Disable Cookies Enabled Disabled

Cookie Policy

To access further regulatory disclosures concerning our Cookie Policy , tracking mechanisms, and corporate data governance,. You will find definitive guidance on how to audit, restrict, or remove these cookies through your enterprise web browser settings.

Enable All Reject All Save Changes

POTOMAC, Maryland – September 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer’s dementia. 

  • Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026 

CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen the evaluable dataset for end-of-treatment, secondary, and exploratory analyses. Following the protocol-defined six-week treatment period, final participant dosing is expected to complete in early November, after which the Company expects to proceed toward database lock, unblinding, and topline analysis, with topline results expected in the fourth quarter of 2026. 

“With target enrollment complete, CALMA has officially transitioned from recruitment to the final stage ahead of topline results,” said Ram Mukunda, Chief Executive Officer of IGC Pharma. “Our focus is now on patient follow-up and database lock as we prepare this 168-patient dataset for rigorous scientific and regulatory evaluation and potential next-stage development.” 

CALMA is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial evaluating IGC-AD1, an investigational oral solution dosed twice daily for six weeks, for agitation in Alzheimer’s dementia. The primary endpoint is change in agitation from baseline to week six on the Cohen-Mansfield Agitation Inventory. The trial was conducted across clinical sites in the United States and Canada, including academic and specialty centers such as Baycrest Academy for Research and Education, Butler Hospital – Memory and Aging Program, Hamilton Health Sciences, McGill University, and Miami Jewish Health.

The enrolled population had an average age of approximately 78 years, reflecting an older Alzheimer’s dementia population, and approximately 53% of participants were female. Based on available race data, approximately 77% of participants were White, 16% were Black or African American, and the remaining participants identified as other races or were not listed. 

Agitation is one of the hardest symptoms of Alzheimer’s dementia for families and caregivers to manage. It can contribute to emergency care, caregiver distress, earlier placement in residential care, and increased healthcare costs.  IGC-AD1 is being developed as a potential treatment option for this high-burden patient population.  

The Data Safety Monitoring Committee has conducted periodic safety reviews and at each review to date, has recommended that the trial continue without modification. The Company remains blinded to treatment assignment. As of the Company’s most recent safety reporting, blinded safety monitoring had not identified any treatment-related serious adverse events as related to study treatment. Safety data remain subject to final review and analysis after database lock and unblinding. 

“Completing enrollment is a defining clinical milestone for IGC Pharma,” Mr. Mukunda continued. “We are grateful to the participants, caregivers, investigators, and clinical teams who made CALMA possible, and we look forward to reporting topline results.” 

About IGC-AD1 and CALMA 

IGC-AD1 is IGC Pharma’s lead investigational therapeutic candidate for agitation in Alzheimer’s dementia. CALMA is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 in this population. The trial’s primary efficacy endpoint is change in agitation as measured by the Cohen-Mansfield Agitation Inventory, a commonly used clinical assessment of agitation behaviors in dementia. 

About IGC Pharma 

IGC Pharma, Inc . (NYSE American: IGC) is a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease and other indications. The Company’s lead asset, IGC-AD1, is being evaluated in the Phase 2 CALMA  clinical trial for agitation associated with Alzheimer’s dementia. The Company is also developing AI-enabled tools intended to support biomedical discovery, data harmonization, and clinical development. 

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Phase 2 CALMA trial, final participant dosing, participant visits and follow-up, database lock, unblinding, data analysis, anticipated timing of topline results in the fourth quarter of 2026, clinical and regulatory development plans for IGC-AD1, safety monitoring, AI-enabled data science capabilities, potential next-stage development planning, and future clinical milestones.  These statements are based on current expectations, estimates, and projections and involve known and unknown risks and uncertainties that could cause actual results, timelines, or outcomes to differ materially from those expressed or implied. Such risks and uncertainties include, among others, risks related to clinical trial timelines and outcomes; patient follow-up; data quality, reconciliation, and evaluability; database lock and statistical analysis; safety and efficacy results; regulatory feedback or approvals; financing needs; third-party service providers; software development and validation; and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. 

Prompts

IGC Pharma, Inc. (ticker IGC), listed in United States.

Company History

Date Change Detail
May 8, 2023 Renamed INDIA GLOBALIZATION CAPITAL, INC. → IGC PHARMA, INC.

ETFs Holding IGC Pharma, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 0.43% 872,689 $ 163.978K Nov 17, 2026